Jinwon Life Sciences Subsidiary VGXI Acquires Land for New Manufacturing Facility Expansion... Enters Design Phase

[Asia Economy Reporter Jang Hyowon] Genexine announced on the 7th that its subsidiary VGXI, a contract development and manufacturing organization (CDMO) specializing in DNA vaccines and gene therapies, has completed the purchase of land for the construction of a new production facility.

The company explained, "The site is located in Desion Technology Park in Conroe, Texas, USA, covering 21 acres (approximately 26,300 pyeong), and we also have an option to purchase an additional 21 acres for future expansion."

It added, "In cooperation with the developer BE&K, we are currently conducting detailed design work for groundbreaking within the third quarter of this year, and plan to complete construction by the third quarter of next year, with operations from the first phase expansion scheduled for the first quarter of 2022."

A company official stated, "According to the overall schedule set for rapid production capacity and facility expansion, the first phase expansion includes multiple manufacturing units, enabling production capacity to exceed 500% immediately upon completion. Flexibility within each GMP zone allows support for a wide range of products from early clinical trials to commercial production."

They also explained, "The new facility includes a micro-process manufacturing zone for small-scale production and a dedicated space for GMP production of RNA."

Park Younggeun, CEO of Genexine, said, "As DNA immunotherapies and gene therapies succeed in clinical research, demand for high-quality and reliable plasmid production services has surged. As the gene therapy industry matures, VGXI will continuously pursue new manufacturing facilities through the first phase expansion and further expansions to support the successful development of our customers' products."

This content was produced with the assistance of AI translation services.